CytoSorbents Corporation announced its participation in the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference on September 9-10 in New York City. CEO Dr. Phillip Chan and CFO Peter Mariani will present to investors and hold meetings, highlighting the company's blood purification technologies used in critical care and cardiac surgery. This event offers CytoSorbents a platform to engage with investors and discuss regulatory progress and product developments, including their DrugSorb®-ATR system seeking FDA approval. The conference gathers key players in biotech and healthcare, providing networking and growth opportunities for CytoSorbents.
Balchem Corporation reported strong Q3 2026 results with net sales of $290.7 million, up 8.6% year-over-year, and net earnings of $46.7 million, a 16% increase. Growth was driven by all three segments: Human Nutrition and Health, Animal Nutrition and...
eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...
S&P Global Ratings has upgraded EssilorLuxottica's long-term credit rating to A+ with a stable outlook, recognizing the company's strong organic growth, solid cash flow, and robust balance sheet. The rating agency highlighted EssilorLuxottica's strat...
EssilorLuxottica announced that S&P Global Ratings has upgraded its long-term credit rating to A+ with a stable outlook. This upgrade recognizes the company's strong organic growth, consistent cash generation, and solid financial position. S&P also h...
Questrade now offers pre-market (7:30 am to 9:25 am ET) and post-market (4:00 pm to 4:15 pm ET) trading for equity options on 29 selected stocks and ETFs, including major names like AAPL and TSLA. This allows investors to respond to earnings reports ...
